DAV regimen
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea;4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-5-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-6-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
Molecular Identity
DAV regimen
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitrosourea;4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide;methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-5-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-6-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
PubChem CID: 135659043
2D Structure
Properties
C61H79ClN16O13
Molecular Formula
1279.80
Molecular Weight
g/mol
1278.5701
Exact Mass
Da
384
TPSA
May have limited oral absorption
7
H-Bond Donors
23
H-Bond Acceptors
2260
Complexity
SMILES
Canonical SMILES
SMILES: CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C6=C(C=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O.CN(C)N=NC1=C(NC=N1)C(=O)NIsomeric SMILES
SMILES: CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C6=C(C=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O.CN(C)/N=N/C1=C(NC=N1)C(=O)NSynonyms(9)
DAV regimenDacarbazine / Vincristine / Nimustine regimenADE protocolDAE protocolAML-BFM 83 protocolRefChem:131017DAV protocolDAVC038381000
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to DAV regimen
Loading drug network...